Ocugen, Inc. Gains 36.88%

Ocugen, Inc. (OCGN:NASDAQ) jumped higher at $10.95, a gain of 36.9%. On Thu 25 Feb 21, OCGN:NASDAQ touched a New 2-Week Low of $8. The stock got featured on our News Catalysts scanner on Fri 26 Feb 21 at 08:42 AM in the 'BIOTECH' category. From Thu 11 Feb 21, the stock recorded 33.33% Up Days and 50.00% Green Days

The stock spiked on Mon 08 Feb 21 at $18.77 with a volume of 719M+.

About Ocugen, Inc. (OCGN:NASDAQ)

Ocugen Inc is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases. Its product candidate includes OCU200 and OCU300 to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet age-related macular degeneration (AMD).